natgillin/translations-raw huggingface dataset:
Ultrafiltration device Vivaflow 200, cut off 5000D (RC, PES or HydroSart)—Sartorius or equivalent; 
Oprema - < Ultrafiltracijska oprema Vivaflovv 200, opsega 5000D (RC, PES ili HydroSart) -Sartorius ili njegov ekvivalent;
The receptor tyrosine kinases are of particular importance in the transmission of mitogenic signals that initiate cellular replication. 
Receptorske kinaze imaju veliki značaj u prijenosu mitogenih signala koji iniciraju staničnu replikaciju.
Number of the Maggots on the % of removed 
Broj objave europskog patenta:
A method according to claim 1, wherein transporting the slurry comprises conveying compressed gas to the seabed to assist in transporting the slurry to the surface. 
Metoda u skladu s patentnim zahtjevom 1, pri čemu korak 2 obuhvaća prenošenje stlačenog plina na morsko dno (3) radi pomoći u transportu mulja na površinu.
Compound of formula (I) according to claim 1, wherein wherein R9 and R9' are as defined in claim 1. 
Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da pri čemu su R9 i R9’ kako je definirano u patentnom zahtjevu 1.
The present invention also provides a pharmaceutical composition comprising a compound of the invention and at least one pharmaceutically acceptable carrier. 
Farmaceutski sastav koji se + iz spoja ili farmaceutski prihvatljive soli iz patentnog zahtjeva 1 i najmanje jednog farmaceutski prihvatljivog nosača.
Use of an anti-C5 antibody, an inhibitor of IL-2, and an immunosuppressive drug in the manufacture of a medicament or medicament package for prolonging survival of a kidney allograft in a recipient mammal, wherein said immunosuppressive drug is not associated with significant nephrotoxicity, and wherein the anti-C5 antibody inhibits cleavage of complement component C5 into fragments C5a and C5b. 
Uporaba anti-C5 antitijela, inhibitora IL-2 i imunosupresivnog lijeka u izradi medikamenta ili pakovanja medikamenta za produženje preživljavanja bubrežnog transplantata u sisavcu primatelju, naznačena time, što HR P20150182 T1 spomenuti imunosupresivni lijek nije udružen sa značajnom nefrotoksičnošću i pri čemu anti-C5 antitijelo inhibira sječenje C5 komponente komplementa na dijelove C5a i C5b.
The FTI for use of any one of claims 1 to 10, wherein said FTI is administered for a period of one to seven days; and/or wherein said FTI is administered on days 1-7 and 15-21 of a 28-day treatment cycle; and/or 
Spoj za uporabu u skladu s patentnim zahtjevom 1, pri čemu je tipifarnib primjenjivan u razdoblju od jednog do sedam dana. Spoj za uporabu u skladu s patentnim zahtjevom 1, pri čemu je tipifarmib primjenjivan 1-7. i 15-21. dana 28-dnevnog ciklusa liječenja.
An amorphous form comprising the compound of the following formula, or a pharmaceutically acceptable salt thereof: 
Amorfni oblik sadrži tvar sljedeće formule, ili njenu farmaceutski prihvatljivu sol:
The process of claim 1 further comprising supplying the second contact zone liquid effluent to the first contact zone. 
Postupak sukladno patentnom zahtjevu 1, nadalje sadrži tekući efluent (10) druge zone kontakta do prve zone kontakta (3).
grams (g) of ceftriaxone sodium, calculated as ceftriaxone free acid; 
(a) spomenuti ceftriakson natrij u količini od 0.125 g, preračunato kao ceftriaksonska slobodna kiselina,
60 A compound of Formula (I) 
Spoj formule (1) naznačen time, da
Methods Of Application Of The Cream: 
Datum objave europske prijave patenta:
After two hours at reflux, the EtOH was eliminated at reduced pressure; 150 mL of water and 150 mL of AcOEt were added. 
Nakon dva sata pod refluksom, EtOH se odstrani pod smanjenim tlakom; doda se 150 mL vode i 150 mL AcOEt.
The mixing and kneading machine (1) as set forth in claim 3, characterized in that the pitch of the screw vanes (4) is adapted to the length of the processing space (6) such that the product residence time in the machine at rotational speeds of the screw shaft (3) exceeding 500 rpm is maximally 20 seconds. 
Stroj za miješanje i gnječenje(1) sukladno zahtjevu 3 ili 4, naznačen time što je vrh vijaka lopatica (4) prilagođen duljini procesne komore (6) na način da je vrijeme počeka proizvoda u stroju pri rotacijskoj brzini osovine (3) koja prelazi 500 rpm najviše 20 sekundi.
The adherent composition of claim 1, wherein an application quantity of 4 to 8 g is completely dissolved off after 100 to 200 flushing operations. 
Ljepljivi pripravak prema jednom od prethodnih zahtjeva, naznačen time da se nanesena količina od 4 do 8 g potpuno otopi nakon 100 do 200 postupaka ispiranja.
This has a significant effect on the method of formulating the solid drug and can also affect the bioavailability of the drug. 
To znatno utječe na postupak formuliranja čvrstog lijeka, a također može utjecati i na biodostupnost lijeka.
The method according to any one of the preceding claims, CHARACTERIZED IN THAT 1 to 6 weight% of solid mineral alkaline in powder form and 0.1 to 5 weight% of concentrated mineral acid and is used, based on the weight of the ammonium nitrate-based particles. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da se koristi 1 do 6 % težinskih udjela krute mineralne lužine u praškastom obliku i 0,1 do 5 % težinskih udjela koncentrirane mineralne kiseline, u odnosu na težinu čestica na bazi amonijeva nitrata.
Freight container according to any one of the preceding claims, further comprising a sensor, especially a temperature sensor, associated with the cargo space, and a controller for controlling the air conditioning unit, wherein said controller is arranged for determining whether an air property sensed by the sensor needs to be altered by examining whether the sensed air property is below a predetermined bottom threshold value and/or above a predetermined top threshold value, and for controlling the air conditioning unit such as to alter the air property accordingly. 
Teretni kontejner sukladno bilo kojem od prethodnih patentnih zahtjeva, još sadrži senzor, posebno senzor temperature, povezan s teretnim prostorom, i regulator za reguliranje jedinice za klimatiziranje zraka, pri čemu je navedeni regulator postavljen za utvrđivanje da li osobine zraka detektiran senzorom treba biti promijenjeno utvrđivanjem je li registrirana osobina zraka ispod unaprijed određene donje granične vrijednosti i/ili iznad unaprijed određene gornje granične vrijednosti, i za reguliranje jedinice za klimatiziranje zraka tako da se u skladu s time promijene osobine zraka.
Said aseptic housing can include a sealed removable cover, an inlet distribution means, an optional exit distribution means, and the necessary support means required to locate and secure the growth surfaces in the culture device. 
Uređaj u skladu s patentnim zahtjevom 7 pri čemu navedeno aseptički zabrtvljeno kućište obuhvaća zabrtvljeni pokrov koji se može ukloniti, sredstvo za ulaznu raspodjelu, opcionalno sredstvo za izlaznu raspodjelu i neophodno sredstvo za potporu potrebno za lociranje i osiguravanje površina rasta u uređaju za kultiviranje.
This embodiment can be represented by Formula (Ia) as illustrated below: wherein each variable in Formula (Ia) has the same meaning as described herein, supra and infra. 
Taj oblik se može prikazati Formulom (Ia) koja je prikazana dolje: HR P20060286 T3 (ag gdje svaka varijabla u Formuli (Ia) ima isto načenje kao što je opisano u tekstu, supra i infra.
CRL-9096] when expressed therein; and/or an amount of bisectingGlcNAc structures on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the protein molecule of said antibody molecules in said antibody molecule composition which is at least 20% higher compared to the same amount of antibody molecules in at least one antibody molecule composition of the same antibody molecule isolated from CHOdhfr- [ATCC No. 
CRL-9096 (CHOdhfr-) kada se tamo eksprimira; i/ili (vi) količinu struktura s račvanim GleNAc na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli protutijela kod navedenih molekula protutijela u navedenom pripravku s molekulom protutijela koja je najmanje 20% veća u usporedbi s istom količinom molekula protutijela u pripravku s najmanje jednom molekulom protutijela za istu molekula protutijela izoliranu iz ATCC No.
The treatment of claim 9, wherein the neurological and psychiatric disorder is schizophrenia. 
Terapija prema zahtjevu 9, naznačena time da neurološki 1 psihijatrijski poremećaj je shizofrenija.
carbonating the aqueous suspension of the divalent metal ion hydroxide obtained in step (c) with a carbon dioxide containing compound in order to obtain fine precipitated divalent metal ion carbonate particles; 
karbonatiranja rezultirajuće reakcijske smjese iz koraka (f) kako bi se dobilo istaloženi karbonat dvovalentnog metalnog iona kao produkt s povećanom svjetlinom u usporedbi s česticama istaloženog karbonata dvovalentnog metalnog iona dobivenog u koraku (d).
The compound for use according to claim 7 wherein the virus is selected from the group consisting of dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus. 
Tvar za uporabu u skladu s patentnim zahtjevom 7 pri čemu je virus odabran iz grupe koja se sastoji od dengue virusa, virusa žute groznice, West Nile virusa, virusa japanskog encefalitisa, virusa krpeljnog encefalitisa, virusa Kunjin, virusa Murray Valley encefalitisa, virusa St. Louis encefalitisa, virusa Omsk hemoragične groznice, virusa goveđe virusne dijareje, Zika virusa 1 virusa hepatitisa C.
The peptide compound according to claim 1, wherein Xaa1 is an aromatic amino acid. The peptide compound according to claim 10, wherein Xaa1 is Tyr or Phe. 
Peptidni spoj prema patentnom zahtjevu 1 ili 2, naznačeno time što je Xaa1 aromatična aminokiselina, pri čemu poželjno Xaa1 predstavlja Tyr ili Phe.
The polymorph of claim 14 obtained by crystallizing a tosylate salt of Compound 1: from acetone, methyl ethyl ketone, methyl pentanone or ethyl acetate. 
Polimorf u skladu s patentnim zahtjevom 14, naznačen time što se dobiva kristaliziranjem tosilatne soli Spoja 1: [image] iz acetona, metil-etil-ketona, metilpentanona ili etil-acetata.
wherein the support further comprises a housing (104) accommodating said energy absorption means (112, 114, 116, 118). 
(ili) u čemu nosač nadalje sadrži kućište (104) u kojem se smještaju navedena sredstva za apsorpciju energije (112,
at least one fatty/ lipophilic component, in a quantity between 0% and 50% by weight of the formulation, 
- najmanje jednu masnu odnosno lipofilnu komponentu, u količini između 0 % i 50 %, težinski, formulacije,
A process for preparing compound 3, which comprises: 
Postupak za pripremu spoja 3, koji se sastoji od:
A method for joining aluminium components, in particular for closing an end part (6) of an aluminium heating radiator element (1), comprising the steps of: 
HR P20171116T1 PATENTNI ZAHTJEVI Postupak zatvaranja krajnjeg dijela (6) elementa aluminijskog radijatora za grijanje (1), naznačen time, da obuhvaća sljedeće korake:
The compound of clause 1, wherein R1 is H or CH3; R2 is H or CH3; R3 is nitrogen protecting group; and one of R4 and R5 is H, and the other is -CH2-X, wherein X is phenyl or heteroaryl including from 5 to 6 ring atoms wherein 1, 2, or 3 of the ring atoms are independently selected from the group consisting of N, NH, N(C1-C3 alkyl), O, and S; each optionally substituted with from 1-3 substituents independently selected from the group consisting of halogen, cyano, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, and -N(R')R'. 
Ri je H ili CH3; R> je H ili CH;; Rs je skupina koja štiti dušik; 1 jedan od Ry 1 Rs je H, 1 drugi je -CH2-X, pri čemu X je fenil ili heteroaril uključujući od 5 do 6 atoma prstena pri čemu su 1, 2, ili 3 od atoma prstena neovisno odabrani od skupine koja se sastoji od N, NH, N(C,-C; alkila), O 1 S; pri čemu je svaki izborno supstituiran s od 1-3 supstituenata neovisno odabranih od skupine koja se sastoji od halogena, cijano, Ci-Cg alkila, hidroksila, C,-C4 alkoksi i -N(R')R';
represents hydrogen or halogen, Z represents a bond or an alkyl-chain having one, two, three or four carbon atoms, whereby the alkyl-chain may be substituted with one, two, three or four substituents, selected independently of one another from the group consisting of carboxy, aminocarbonyl and (C1-C4)-alkyl, 
predstavlja vodik ili halogen, Z predstavlja vezu ili alkilni lanac s jednim, dva, tri ili četiri atoma ugljika, gdje alkilni lanac može biti supstituiran s jednim, dva, tri ili četiri supstituenti, koje se međusobno neovisno bira iz skupine koju čine karboksi, aminokarbonil i (C1-C4)-alkil, gdje pak alkil može biti supstituiran sa supstituentom kojeg se bira iz skupine koju čine hidroksi, karboksi i aminokarbonil, Y predstavlja vezu, O, NH ili S, A predstavlja (C6-C10)-aril ili 5- do 10-eročlani heteroaril, gdje su aril i heteroaril supstituirani sa supstituentom sljedeće formule [image] ili [image], gdje
The roll of any of the preceding claims, wherein the microstructure is present at least in a working layer of the roll. 
Valjak prema prethodnim zahtjevima, pri čemu se mikrostruktura nalazi u najmanje jednom radnom sloju valjka
The aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. 
Vodene otopine su posebno prikladne za intravenoznu, intramuskularnu, potkožnu i intraperitonealnu primjenu.
A further aspect of the instant invention involves the “novel” compositions comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a compound of formula (Ia), in free or salt form and, where possible, in acid addition salt form. 
Daljnji oblik sadašnjeg izuma uključuje "nove" sastave koji sadrže farmaceutski prihvatljiv nosač ili sredstvo za razrjeđivanje i terapeutski učinkovitu količinu spoja formule (Ia) u slobodnom obliku ili u obliku soli i, gdje je to moguće, u obliku kiselinske adicijske soli.
The use of claim 6, wherein the non-Hodgkin's lymphoma is follicular B-cell non-Hodgkin lymphoma. 
Upotreba prema zahtjevu 6, naznačena time da ne-Hodgkinov limfom predstavlja folikularni B-stanični ne-Hodgkinov limfom.
The anti-TSLP human antibody of claim 1, wherein said anti-TSLP human antibody comprises a) a light chain comprising a light chain variable domain comprising the amino acid sequence as set forth in SEQ ID NO:363 and a lambda light chain constant domain comprising the amino acid sequence as set forth in SEQ ID NO:369; and b) a heavy chain comprising a heavy chain variable domain comprising the amino acid sequence as set forth in SEQ ID NO:361 and an IgG2 heavy constant domain comprising the amino acid sequence as set forth in SEQ ID NO:365. 
15. Anti-TSLP ljudsko protutijelo iz patentnog zahtjeva 1, pri čemu navedeno anti-TSLP ljudsko protutijelo sadrži a) laki lanac koji sadrži varijabilnu domenu lakog lanca koja sadrži aminokiselinski slijed pretpostavljen u SEQ ID NO:363 i konstantnu domenu lambda lakog lanca koja sadrži aminokiselinski slijed pretpostavljen u SEQ ID NO:
A pharmaceutical composition comprising (a) 2-chloro-2'-deoxyadenosine or pharmaceutically acceptable salts thereof, (b) an anti-alpha-4 integrin antibody which blocks the adhesion of monocytes and leukocytes to endothelial cells; and a pharmaceutically acceptable carrier, diluent or excipient thereof. 
Farmaceutski pripravak, naznačen time, da sadrži (a) 2-kloro-2'-deoksiadenozin ili njegove farmaceutski prihvatljive soli, (b) anti-alfa-4 integrin antitijelo koje blokira adheziju monocita i leukocita na endotelne stanice; te farmaceutski prihvatljivu podlogu, sredstvo za razrjeđivanje ili pomoćnu tvar. t>&
at least in part drying the strands of wood, 
barem djelomično sušenje drvenih vlakana,
The term “pro-drugs” refers to compounds that have been modified with specific chemical groups known in the art and when administered into an individual these groups undergo biotransformation to give the parent compound. 
Izraz "pro-lijekovi" označava spojeve kojisu bili modificirani sa specifičnim kemijskim skupinama poznatim u struci i kada se primjene pojedincu, te skupine podliježu biotransformaciji da bi se dobio polazni spoj.
A therapeutically effective amount of a compound of the present invention can be used for the preparation of a medicament useful for treating Syndrome X, diabetes, treating obesity, lowering tryglyceride levels, raising the plasma level of high density lipoprotein, and for treating, preventing or reducing the risk of developing arteriosclerosis, and for preventing or reducing the risk of having a first or subsequent atherosclerotic disease event in mammals, particularly in humans. 
HR P20070422 T3 Terapijski djelotvorna količina spoja prema ovom izumu može se upotrijebiti u pripravi lijeka korisnog za liječenje Sindroma X, dijabetesa, liječenje pretilosti, snižavanje razina triglicerida, podizanje razina lipoproteina visoke gustoće u plazmi, te za liječenje, sprječavanje ili smanjivanje rizika od razvoja arterioskleroze, te za sprječavanje ili smanjivanje rizika od primarne ili naknadne pojave aterosklerotske bolesti kod sisavaca, osobito kod ljudi.
a composition like that indicated in Example 1, without hydroxypropyl chitosan 
- - pripravak poput onog navedenog u Primjeru 1, bez hidroksipropil hitosana
Pharmaceutical according to any one of claims 8 - 10, characterized in that the active substances are presented in fixed or free combination for simultaneous, sequential or separate administration together with the usual excipients, adjuncts, and additives in a pharmaceutical form suitable for inhalative application. 
Farmaceutski proizvod sukladno bilo kojem od patentnih zahtjeva 5 do 7, naznačen time, da je djelatna tvar nazočna u fiksiranoj ili slobodnoj kombinaciji za istovremeno, povremeno ili odvojeno davanje zajedno s uobičajenim ekscipijensima, adjunktima i aditivima u farmaceutskom obliku prikladnome za inhalatornu primjenu.
The pharmaceutical composition according to claim 31, characterized in that the osteoporosis is postmenopausal osteoporosis, senile osteoporosis, secondary osteoporosis due to the use of a therapeutic agent such as a steroid or an immunosuppressant, or osteoporosis accompanying rheumatoid arthritis. 
Farmaceutski pripravak za uporabu sukladno zahtjevu 19, karakteriziran time što je osteoporoza postmenopauzalna osteoporoza, staračka osteoporoza, sekundarna osteoporoza uzrokovana uporabom terapeutika kao što su steroidi ili imunosupresivi, ili osteoporoza koja prati reumatoidni artritis.
12, except that the tip of the grounded electrode is a plane 37 and the tip of the high-voltage electrode 37 a is pointed like a needle. 
Sustav prema zahtjevu 7, pri čemu su prvi vrh prve elektrode (2b.1) i drugi vrh druge elektrode (2b.2) ravni.
The compound of claim 1, wherein the compound is: 
Spoj u skladu sa patentnim zahtjevom 1, koje je:
Use of E 82, wherein the IL-17 antagonist binds to and inhibits the activity of IL-17, IL-17RA or IL-17RC. 
Uporaba u skladu sa zahtjevom 82, naznačena time, da se IL-17 antagonist veže na i inhibira djelovanje IL-17, IL- ITRA ili IL-17RC.
According to still another embodiment the liquid coating formulation used to form an absorptive layer further contains a dispersant, preferably polyacrylate, in an amount of 0.05 to 5 wt.-%, and preferably in an amount of 0.5 to 5 wt.-%, based on total weight of the pigment. 
Postupak prema zahtjevima 17 do 19, naznačen time da tekuća formulacija premaza koji se koristi za dobivanje apsorpcijskog sloja dalje sadrži sredstvo za disperziju, poželjno poliakrilat, u količini od 0.05 do 5 tež-%, i poželjno u količini od 0.5 do 5 tež-%, u odnosu na ukupnu težinu pigmenta.
The use of a compound as defined in any one of claims 1 to 12 in the preparation of an agent for the treatment or prevention of allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity (including contact dermatitis), conjunctivitis, especially allergic conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis and Crohn's disease, mastocytosis, autoimmune diseases such as hyper IgE syndrome and systemic lupus erythematus, psoriasis, acne, multiple sclerosis, allograft rejection, reperfusion injury, chronic obstructive pulmonary disease, rheumatoid arthritis, psoriatic arthritis and osteoarthritis. 
Upotreba spoja kao što je definiran prema bilo kojem od zahtjeva od 1 do 12, naznačena time, da je za pripremu sredstva za liječenje ili prevenciju alergijske astme, perenijalnog alergijskog rinitisa, sezonskog alergijskog rinitisa, atopičnog dermatitisa, kontaktne preosjetljivosti (uključujući kontaktni dermatitis), konjuktivitisa, posebno alergijskog konjuktivitisa, eozinofilnog bronhitisa, alergije na hranu, eozinofilnog gastroenteritisa, upalne bolesti crijeva, ulceroznog kolitisa i Crohnove bolesti, mastocitoze, autoimunih bolesti poput hiper IgE sindroma i sistemnog eritematoznog lupusa, psorijaze, akni, multiple skleroze, odbacivanja alotransplantata, reperfuzijsko ozljede, kronične opstruktivne plućne bolesti, reumatoidnog artritisa, psorijaznog artritisa i osteoartritisa.
The pharmaceutical composition of claim 13, wherein the proliferative disorder is cancer. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 13, naznačen time što je proliferativni poremećaj rak.
In accordance with another aspect of the invention there is also provided a process for the preparation of a pharmaceutical formulation including admixing a compound of the present invention with one or more pharmaceutically acceptable carriers, diluents or excipients. 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 1 do patentnog zahtjeva 3, kao i jednu ili više farmaceutski prihvatljivih pomoćnih tvari.
is an 8- to 10-membered heteroaryl group containing 1 to 4 heteroatoms independently chosen from N, O, and S, wherein J2 is optionally substituted with one or more substituents independently chosen from amino, cyano, hydroxyl, halogen, C1-C4alkyl, C1-C4alkoxy, mono-and di- C1-C4alkylamino, C1-C2haloalkyl, and C1-C2haloalkoxy; 
je 8- do 10-člana heteroaril grupa koja sadrži 1 do 4 heteroatoma neovisno izabrana iz N, O, i S, pri čemu je J2 opcionalno susptituiran s jednim ili više supstituenata neovisno izabranih iz amino, cijano, hidroksil, halogen, C1-C4 alkil, C1-C4 alkoksi, mono-i di- C1-C4 alkilamino, C1-C2 haloalkil, i C1-C2haloalkoksi;
preparing the compounds of formula (V-a) in a single step by reacting the intermediate of formula (VI), with 1,4-dioxane-2,5-diol and the appropriate boronic acid of formula (VII), wherein R1 is as defined above or 
NON OH R (V-a) (v) b) pripremanje spoja sa formulom (V-a) u jednom koraku uz pomoć reakcije intermedijera sa formulom (VI) sa 1,4-35
Measurement of a substituted uracil in simulated gastric fluid and simulated intestinal fluid. 
Mjerenje supstituiranog uracila u simuliranoj želučanoj tekućini 1 simuliranoj crijevnoj tekućini.
After stirring at room temperature for 20 minutes the reaction mixture is evaporated to dryness. 
Nakon miješanja 20 minuta pri sobnoj temperaturi reakcijsku smjesu se ispari do suhog.
a model of the environment is created by an operator of the control system by defining a plurality of cells corresponding to areas of said environment, 
da je rukovalac sustava kontrole načinio model prostora odredivši veći broj ćelija koje odgovaraju dijelovima toga prostora,
A packaging according to claim 1, wherein at least one of the inner part and the first and second outer parts comprises locking means for keeping the packaging in a closed position. 
Pakiranje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time, što unutarnji dio i/ili prvi i drugi vanjski dio sadržavaju sredstvo za blokiranje koje drži pakiranje u zatvorenom položaju.
heating the ends of the material as a result of the resistance welding (40); 
Grijanje krajeva materijala, kao rezultat otpornog zavarivanja (40);